HR and breast cancer: Although it has been shown that PD-L1-positive BCs frequently exhibit high levels of TILs and a lack of expression of ER, PR, and HER2, and that patients affected by TNBC are the ones who may benefit the most from immunotherapy, promising results have been obtained in some trials also for patients with HR+ and/or HER2+ BC [63].